– Mindray expands its cardiac biomarker portfolio with cutting-edge hs-cTnI and NT-proBNP assays, improving cardiovascular disease care
SHENZHEN, China, Oct. 23, 2023 /PRNewswire/ — Mindray (SZSE: 300760), a global leader in medical devices and solutions, introduces cardiac biomarkers high sensitivity troponin I (hs-cTnI) and NT-proBNP. The additions have enhanced Mindray’s diverse portfolio of cardiac biomarkers for the diagnosis and management of cardiovascular diseases (CVD).
Although CVD is the leading cause of death worldwide, its early detection is key to saving lives. The guidelines recommend the use of cTnl and NT-proBNP as essential biomarkers for suspected acute coronary syndrome (ACS) and heart failure in early screening, risk stratification, rapid diagnosis and therapeutic follow-up.
The two assays are a collaboration between Mindray and HyTest, a Mindray company and a leading global supplier of antibodies and antigens. HyTest, known for its expertise in cardiac biomarkers, had its cardiac troponin complex material selected as an international troponin standard by the AACC in 2004.
Both tests, validated by the Wuhan Asian Heart Hospital in China and the Hennepin Healthcare Research Institute in the USA, present excellent clinical performance.
Mindray hs-cTnI Assay: Reliable Detection of Myocardial Injury with High Detection Rate and Low CV
Mindray’s hs-cTnI assay far exceeds the minimum requirements for hs-cTn by achieving a remarkable detection rate of 93% between LoD and 99th RLU and an imprecision CV of less than 5% at 99th RLU. This demonstrates the exceptional sensitivity, precision and reliability of the assay in the detection of myocardial lesions. Additionally, a 0-2h diagnostic algorithm study conducted at Hennepin Healthcare Research Institute further supports its effectiveness in diagnosing and treating cardiac conditions within this crucial timeframe.
Mindray NT-proBNP assay with high precision and strong anti-interference ability
NT-proBNP is an established cardiac marker for heart failure and its treatment. Mindray’s NT-proBNP assay demonstrates high accuracy with a CV of ≤5% and effectively minimizes interference from 55 common heart disease medications, demonstrating its reliability for the detection and management of heart failure.
“By integrating HyTest’s pioneering antibodies and cardiac biomarker research with Mindray’s advanced reagent technology and platform, we will offer more reliable solutions that will bring better outcomes to patients in the field of cardiovascular diseases and beyond” said Dr. Jianwen He, Chief Scientific Officer of Mindray IVD.
About Mindray
Mindray is one of the leading developers, manufacturers and suppliers of medical devices and solutions, providing healthcare professionals around the world with innovative, life-saving tools in the areas of patient monitoring and life support, in vitro diagnostics, diagnostic imaging and orthopedics.
Website: https://www.mindray.com/en
Photo – https://mma.prnewswire.com/media/2254472…Photo – https://mma.prnewswire.com/media/2254473…
View original content: https://www.prnewswire.com/news-releases/mindray-amplia-su-cartera-de-biomarcadores-cardiacos-con-los-vanguardistas-ensayos-hs-ctni-y-nt-probnp-301964596.html
